A Multicenter Double-Blind Trial of Paroxetine Versus Amitriptyline in Depressed Inpatients

Department of Psychiatry, Innsbruck University Hospital, Austria.
Journal of Clinical Psychopharmacology (Impact Factor: 3.24). 08/1994; 14(4):241-6. DOI: 10.1097/00004714-199408000-00003
Source: PubMed


The phenylpiperidine derivative paroxetine is a selective serotonin reuptake inhibitor. In a double-blind 6-week trial, paroxetine was compared with amitriptyline in hospitalized patients suffering from major depression (DSM-III). One hundred fifty-three patients were enrolled in the study in seven centers in Austria and Germany. Results showed similar efficacy of both drugs after 6 weeks. The differences between groups in Montgomery-Asberg Depression Rating Scale and Clinical Global Impression ratings did not reach statistical significance at any time. Side effects were distributed similarly but with a significantly higher incidence of anticholinergic effects in patients treated with amitriptyline (p < or = 0.001), whereas agitation and insomnia were registered more often in the paroxetine group. This study supports the antidepressive efficacy of paroxetine in a sample of severely depressed inpatients.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (SSRI). Ninety-one hospitalised patients with a major depression (DSM-III) aged 65 and over from six Austrian and one German center were entered into the study, which compared the efficacy and tolerability of paroxetine versus amitriptyline. After 6 weeks both groups showed similarly good therapeutic results. In the paroxetine group, 64.3% of the patients had a 50% or more reduction of the HAMD total score compared to 58.1% in the amitriptyline group. Side effects were distributed similarly in both groups. Patients in the paroxetine group showed a higher incidence of anxiety and agitation; anticholinergic side effects were registered more often in the amitriptyline group.
    Psychopharmacology 07/1995; 119(3):277-81. DOI:10.1007/BF02246291 · 3.88 Impact Factor
  • Journal of Clinical Psychopharmacology 11/1995; 15(5):303-5. DOI:10.1097/00004714-199510000-00001 · 3.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effectiveness of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) were contrasted in endogenous/melancholic depression. By reviewing Hamilton Depression Rating data from controlled trials, the data indicate that TCAs are consistently more effective than the SSRIs. Despite the wide use of SSRIs in the treatment of depression, it seems reasonable that clinicians subtype their depressed patients and treat melancholic patients first with a course of TCAs. For melancholic patients who have not responded to a SSRI, pharmacotherapeutic alternatives include (1) a TCA alone; (2) TCA augmentation of the SSRI, or (3) lithium augmentation of the SSRI.
    Journal of Affective Disorders 07/1996; 39(1):1-6. DOI:10.1016/0165-0327(96)00014-6 · 3.38 Impact Factor
Show more